I have no position. but often buy beaten down biotechs that I think can come back - I won't touch this one! Have any of you looked at Balance Sheet? If you take out the Goodwill and Intangibles, their Liabilities exceed their assets by $928 Million - almost a Billion dollars! All they need is for a large revenue drug to be pulled from the market because of an adverse event and they will go bankrupt. Also, don't trust anything Jefferies says, because they are intertwined with AMAG. From 10Q: "on August 17, 2015, in connection with the CBR acquisition, we completed a private placement of $500.0 million aggregate principal amount of 7.875% Senior Notes due 2023 (the “2023 Senior Notes”) and entered into a credit a greement with a group of lenders, including Jefferies Finance LLC (“Jefferies”), as administrative and collateral agent, that provided us with, among other things, a six -year $350.0 million term loan facility (the “2015 Term Loan Facility”). We borrowed the full $350.0 million available under the 2015 Term Loan Facility on August 17, 2015. We used the net proceeds from the August 2015 Offering, discussed below, the offering of the 2023 Senior Notes and borrowings under the 2015 Term Loan Facility along with existing cash to fund the acquisition of CBR, to repay the remaining $323.0 million outstanding principal amount under our then existing five -year term loan facility (the “2014 Term Loan Facility”), and to pay prepayment premiums, fees and expenses in connection with the foregoing. See Note Q, “ Debt ,” for more information.
On August 5, 2015, we sold approximately 3.6 million shares of our common stock at a public offering price of $63.75 per share (the “August 2015 Offering”), resulting in net proceeds to us of approximately $218.6 million.
A buyout takes care of all of these. No need for Apple or RS and entire salesforce replaced by acquiring company's already in place salesforce. They are already in talks.
ATRS will do the same - just keep buying and hold tight. I have been a professional trader since 1987 and 87% of my trades have made money. ATRS is extremely oversold and has an extreme short position and will make a very large move up very soon. Hold tight! My last 3 trades made over $380,000. I expect to make over $150,000 here. Wake up - Do not sell for pennies.
Plus they have $6.5 million in receivables. They'll definitely be bought out if they stay anywhere near this price. They should be trading around $2.50 here, not half that.
This is totally meaningless. Flynn is not an "insider". He is a member of the 10%. ownership group. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. He kept 75% of his shares and only sold 25%. These guys have to roll off some shares to make new investments in other biotechs which they must be constantly doing. Obviously, many shorts saw these sales and interpreted it as bad news, which it is not, and shorted the stock. They are wrong and will pay for it in the near future. That's why I bought in today and will keep buying if ATRS goes lower.
Share price should be over $8. Just hold this and it will be.
MNKD now has a $1.57 Billion Market Cap, even after its huge drop. If BDSI had the same market cap, its share price would be $29.92. I would love this stock to trade just like MNKD.
Who cares........It's meaningless. Don't worry about nonsense. Look at big picture. BDSI is severely underpriced. Buy low, sell high.
Don't forget MEDA ( Meda's sales and marketing organization is distinguished by its efficient structure where the employees in general have a high level of education. Our sales and marketing organization spans all of Europe and the US, as well as an increasing number of growth markets and are currently present in over 60 countries.
At the end of 2014, Meda had around 5,202 employees, 2,996 of which worked in sales and marketing.
Outside Sweden, expansion has taken place both organically and through acquisitions. Sales and marketing are crucial processes in the integration of an acquisition because success depends on the acquired company and its products being quickly integrated and commercialized according to the Meda model. )
I haven't heard anyone mention it, including analysts, but there is another $55 million in milestone payments coming from Endo deal.
(continued) Piper Jaffray analysts believe that BELBUCA is well positioned for success in an evolving treatment landscape for chronic pain, which they believe could translate into peak sales north of $400 million (or roughly $60 million in royalty potential to BDSI).
The analysts point out that the feedback from their survey of 25 pain specialists points to a highly receptive audience. Out of 25 respondents, more than half noted that they would consider writing Rx’s for a buccally- or sublingually-absorbed form of buprenorphine in at least a sizable minority of their patients.
With a combined peak revenue potential from BELBUCA and BUNAVAIL (the company's treatment for opioid dependence), the analysts believe the risk/reward profile of BDSI shares is attractive, and maintained an Overweight rating and a $15 price target for the stock.
Ladenburg Thalmann: BELBUCA Market Opportunity Will Be Significantly Expanded
Finally, Ladenburg Thalmann analyst Matthew Kaplan expressed his bullish conviction, noting, "Based on the positive and statistically robust data from the two pivotal studies, we believe there is a relatively high probability of approval. In addition, based on the potential for BELBUCA to be a Schedule 3 product while DEA has moved hydrocodone products from Schedule 3 to more restrictive Schedule 2, we believe the market opportunity for BELBUCA will be significantly expanded."
The analyst reiterated a Buy rating on BioDelivery shares, with a $21 price target, representing a nearly 200% premium to current levels.
As of this writing, TipRanks has polled 8 analysts who have rated BDSI in the last 12 months. All of the 8 analysts are bullish on the stock with an average 12-month price target of $17.